Barry Stein

President & CEO, Colorectal Cancer Canada

Barry D. Stein, B.Com., B.C.L., LL.B., graduated from McGill University and is a member of the Bar of Quebec. He is President and CEO of Colorectal Cancer Canada, and sits on the board of the Canadian Personalized Healthcare Innovation Network (CPHIN), Le Consortium de recherche en oncologie clinique du Québec (observer) (Q-CROC), FT3- From Testing to Targeted Treatments and formerly Exactis Innovation. He is on the governing council of CANTRAIN the Canadian Consortium of Clinical Trial Training platform and on the Board of Directors of DNA to RNA an inclusive Canadian Approach to Genomic-based RNA Therapeutics (D2R) based at McGill University Research Institute. He is also a member of the Clinical Trials Transformation Initiative CCTI (Duke- Clinical Research Institute Steering Committee. As a survivor of metastatic colorectal cancer diagnosed in 1995, Barry was obliged to seek health care outside of Canada to fight his disease. His judgement, obtained in the Superior Court of Quebec in 1999, serves as a leading precedent in Canada for the reimbursement of out of country health care.